Immunogenicity of a Third Scheduled Dose of Rotarix in Australian Indigenous Infants: A Phase IV, Double-blind, Randomized, Placebo-Controlled Clinical Trial( )

BACKGROUND: Rotarix (GlaxoSmithKline) oral rotavirus vaccine is licensed as 2 doses in the first 6 months of life. In settings with high child mortality rates, clinical protection conferred by 2 doses of Rotarix is reduced. We assessed vaccine immune response when an additional dose of Rotarix was g...

Descripción completa

Detalles Bibliográficos
Autores principales: Middleton, Bianca F, Danchin, Margie, Jones, Mark A, Leach, Amanda J, Cunliffe, Nigel, Kirkwood, Carl D, Carapetis, Jonathan, Gallagher, Sarah, Kirkham, Lea-Ann, Granland, Caitlyn, McNeal, Monica, Marsh, Julie A, Waddington, Claire S, Snelling, Thomas L
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Major Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9624458/
https://www.ncbi.nlm.nih.gov/pubmed/35134951
http://dx.doi.org/10.1093/infdis/jiac038

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9624458/
https://www.ncbi.nlm.nih.gov/pubmed/35134951
http://dx.doi.org/10.1093/infdis/jiac038

Ejemplares similares